Please login to the form below

Not currently logged in

Michael Parini moves from Pfizer to Vertex

Will be the USbiotech's chief legal officer

Vertex Pharmaceuticals has appointed Michael Parini as executive vice president and chief legal officer. 

He joins Boston-based biotech company from Pfizer, where he served for more than a decade, in various leadership roles within the company's global legal team.

Most recently, he served as senior vice president and associate general counsel and was responsible for the strategic management of Pfizer's global litigation activities, including its civil, intellectual property, government and employment litigation.

He said: "I've watched Vertex's evolution over recent years and am thrilled to join this team at such an exciting and pivotal time in the company's history. I believe that Vertex is one of very few companies that has the potential to make a fundamental change in the treatment of many serious diseases.”

Parini will begin his role with Vertex on January 4, 2016, and will also serve as a member of its executive committee, reporting directly to Jeffrey Leiden,

Vertex's chairman, president and chief executive officer. Leiden said: "Michael brings to Vertex extensive global legal experience related to the development and commercialisation of multiple medicines.

“I welcome Michael to the Vertex team and believe his expertise will be invaluable as we bring our cystic fibrosis medicines to more people worldwide and advance key research and development programmes across many diseases.”

Prior to Pfizer, Parini served as a health care attorney at Akin, Gump, Strauss, Hauer & Feld, providing legal counsel on federal and state regulatory and policy issues.

1st December 2015

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge